[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514745":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":33,"locations":44,"responsibleParty":64,"collaborators":68,"id":70,"slug":22,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":22,"enrollmentInfo":79,"targetDuration":22,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":22,"overallStatus":47,"whyStopped":22,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Università Vita-Salute San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A","EXPERIMENTAL","* Candidates to surgery as first treatment regardless of cN\n* ER+ Her2 negative BC with ki67\\>10%",[13,14,15],"Drug: FES","Procedure: PET\u002FMRI A","Genetic: Translational analysis",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","FES","16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET\u002FMRI exam",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"PROCEDURE","PET\u002FMRI A","An additional FES PET\u002FMRI will be performed before surgery.",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":22},"GENETIC","Translational analysis","Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.",[9],[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Rosa Di Micco, MD","CONTACT","+39022643","4565","dimicco.rosa@hsr.it",{"name":41,"role":36,"phone":37,"phoneExt":42,"email":43},"Nicole Rotmensz, MSc","5650","rotmensz.nicole@hsr.it",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"IRCCS Ospedale San Raffaele","RECRUITING","Milan","MI","20132","Italy",{"type":53,"coordinates":54},"Point",[55,56],12.59836,42.78235,{"lat":56,"lon":55},[59,62],{"name":60,"role":36,"phone":61,"phoneExt":22,"email":39},"Rosa Di Micco, MD, PhD","+39 26434565",{"name":41,"role":36,"phone":63,"phoneExt":22,"email":43},"+390226435650",{"type":65,"investigatorFullName":35,"investigatorTitle":66,"investigatorAffiliation":67,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Principal Investigator","IRCCS San Raffaele",[69],{"name":67,"class":6},"100514745",false,"NCT05982496","18F FES-PET\u002FMRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer","18F-FES PET\u002FMRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer: a Phase II Prospective Cohort Study Evaluating the Performance of FES PET\u002FMRI in Axillary Staging Compared With Axillary Surgery","FESTA","Inclusion Criteria:\n\n* Female patients, age\\>= 18 yrs, diagnosed with primary or advanced breast cancer\n* LumA or ER-positive Lobular subtypes\n\n  * candidates to surgery as first treatment regardless of cN\n  * ER-positive Her2 negative BC with ki67\\>10%\n\nExclusion Criteria:\n\n* ER-negative tumors\n* Pregnancy;\n* Contraindication to PET;\n* Contraindication to MRI;\n* Claustrophobia;\n* Allergy to the MR contrast agent;\n* Severe renal insufficiency","FEMALE","18 Years",{"count":80,"type":81},119,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Study hypothesis is that combining the advantages of hybrid PET\u002FMRI and the high sensitivity\u002Fspecificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.",[87,88,89,90,91],"Breast Cancer Female","Lobular Breast Carcinoma","PET\u002FMRI","Axillary Lymphadenopathy","Luminal A Breast Cancer","2026-06-09",{"date":94,"type":95},"2026-06-12","ACTUAL",{"date":92,"type":95},{"date":98,"type":81},"2029-12-01",{"name":5,"class":6},1]